ZA923299B - Nanocrystalline magnetic iron oxide particles - Google Patents
Nanocrystalline magnetic iron oxide particlesInfo
- Publication number
- ZA923299B ZA923299B ZA923299A ZA923299A ZA923299B ZA 923299 B ZA923299 B ZA 923299B ZA 923299 A ZA923299 A ZA 923299A ZA 923299 A ZA923299 A ZA 923299A ZA 923299 B ZA923299 B ZA 923299B
- Authority
- ZA
- South Africa
- Prior art keywords
- iron oxide
- magnetic iron
- oxide particles
- nanocrystalline magnetic
- magnetic particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/189—Host-guest complexes, e.g. cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compounds Of Iron (AREA)
- Hard Magnetic Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Soft Magnetic Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4117782A DE4117782C2 (de) | 1991-05-28 | 1991-05-28 | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA923299B true ZA923299B (en) | 1992-12-30 |
Family
ID=6432830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA923299A ZA923299B (en) | 1991-05-28 | 1992-05-07 | Nanocrystalline magnetic iron oxide particles |
Country Status (15)
Country | Link |
---|---|
US (1) | US5427767A (xx) |
EP (1) | EP0516252B1 (xx) |
JP (1) | JP3306810B2 (xx) |
AT (1) | ATE156021T1 (xx) |
AU (1) | AU653220B2 (xx) |
CA (1) | CA2068632C (xx) |
DE (2) | DE4117782C2 (xx) |
DK (1) | DK0516252T3 (xx) |
ES (1) | ES2106134T3 (xx) |
GR (1) | GR3024898T3 (xx) |
IE (1) | IE921595A1 (xx) |
IL (1) | IL101929A (xx) |
NO (1) | NO305105B1 (xx) |
NZ (1) | NZ242669A (xx) |
ZA (1) | ZA923299B (xx) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0783325B2 (en) † | 1994-09-27 | 2004-03-31 | Amersham Health AS | Contrast agent |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988009152A1 (en) * | 1985-03-19 | 1988-12-01 | Mills Randell L | Apparatus providing diagnosis and selective tissue necrosis |
US5672334A (en) * | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
ATE132758T1 (de) * | 1992-06-01 | 1996-01-15 | Basf Ag | Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln |
ATE156706T1 (de) * | 1993-03-17 | 1997-08-15 | Silica Gel Gmbh | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
WO1995031220A1 (fr) * | 1994-05-12 | 1995-11-23 | Otsuka Pharmaceutical Co., Ltd. | Agent de contraste pour imagerie par resonance magnetique |
DE4419256A1 (de) * | 1994-06-01 | 1995-12-07 | Rau Freiherr Von Nagell Helmut | Verwendung von intravenös applizierbarem Eisen zur Therapie von Tumorerkrankungen und/oder Infektionskrankheiten |
DE4421159C1 (de) * | 1994-06-20 | 1995-08-24 | Thomas Bruns | Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche |
DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
DE19500665A1 (de) * | 1995-01-12 | 1996-07-18 | Axel Prof Dr Haase | Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel |
DE19508772C2 (de) * | 1995-03-01 | 1998-01-29 | Schering Ag | Verfahren und Verbindungen zur Detektion von Analyten mittels Remanenzmessung und deren Verwendung |
US6106866A (en) * | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
US5695901A (en) * | 1995-12-21 | 1997-12-09 | Colorado School Of Mines | Nano-size magnetic particles for reprographic processes and method of manufacturing the same |
AU716667B2 (en) | 1996-01-10 | 2000-03-02 | Nycomed Imaging As | Contrast media |
GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
DE19600744A1 (de) * | 1996-01-11 | 1997-07-17 | Werner Alois Prof Dipl Kaiser | Magnetische Substanz zur lokalen hyperthermischen Behandlung vorwiegend kleiner Tumore |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US5985312A (en) * | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
GB2311138A (en) * | 1996-03-15 | 1997-09-17 | Nycomed Imaging As | ESR-enhanced MRI using magnetic particles as contrast agents |
US20060003163A1 (en) * | 1996-11-16 | 2006-01-05 | Nanomagnetics Limited | Magnetic fluid |
US6713173B2 (en) * | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
AU9661598A (en) * | 1997-09-10 | 1999-03-29 | Yale University | Radiation dosimetry with magnetic resonance detectable compounds |
US6607829B1 (en) * | 1997-11-13 | 2003-08-19 | Massachusetts Institute Of Technology | Tellurium-containing nanocrystalline materials |
US6375634B1 (en) | 1997-11-19 | 2002-04-23 | Oncology Innovations, Inc. | Apparatus and method to encapsulate, kill and remove malignancies, including selectively increasing absorption of x-rays and increasing free-radical damage to residual tumors targeted by ionizing and non-ionizing radiation therapy |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6428811B1 (en) | 1998-03-11 | 2002-08-06 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
US6699724B1 (en) | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
US7101575B2 (en) * | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
EP1104281B1 (en) * | 1998-08-12 | 2011-03-16 | Societe Des Produits Nestle S.A. | Incorporation of exogenous lactic bacteria into the oral microflora |
EP1159951A1 (en) * | 2000-06-02 | 2001-12-05 | Societe Des Produits Nestle S.A. | Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
EP0988864A1 (de) * | 1998-09-23 | 2000-03-29 | Luboldt, Wolfgang, Dr.med. Dipl.-Phys. | Kontrastmittel für die Magnetresonanztomographie |
US6470220B1 (en) * | 1999-03-29 | 2002-10-22 | The Regents Of The University Of California | Diagnosis and treatment of cancers using in vivo magnetic domains |
US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
DE20023081U1 (de) | 1999-06-10 | 2003-01-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 80539 München | Eingekapselte Kristalle mit Mehrlagenbeschichtung |
US6514481B1 (en) | 1999-11-22 | 2003-02-04 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
EP2343047B2 (en) * | 2000-02-08 | 2021-03-17 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
WO2001067105A1 (en) * | 2000-03-06 | 2001-09-13 | Dade Behring Marburg Gmbh | Carriers coated with polysaccharides, their preparation and use |
US20050013775A1 (en) * | 2000-06-01 | 2005-01-20 | Kotov Nicholas A. | Bioconjugates of nanoparticles as radiopharmaceuticals |
WO2001091808A2 (en) * | 2000-06-01 | 2001-12-06 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
DE10042023C2 (de) * | 2000-08-08 | 2003-04-10 | Biognostic Ag | Kapseln, die feste Teilchen signalerzeugender Substanzen einkapseln, und deren Verwendung bei Bioassays zum Nachweis von Zielmolekülen in einer Probe |
US7077859B2 (en) * | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US7153703B2 (en) * | 2001-05-14 | 2006-12-26 | Board Of Trustees Of The University Of Arkansas N. A. | Synthesis of stable colloidal nanocrystals using organic dendrons |
ITTO20011191A1 (it) * | 2001-12-18 | 2003-06-18 | Itw Ind Components Srl | Dispositivo di servizio per un frigorifero e frigorifero provvisto ditale dispositivo. |
IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
US20030185757A1 (en) * | 2002-03-27 | 2003-10-02 | Mayk Kresse | Iron-containing nanoparticles with double coating and their use in diagnosis and therapy |
US7249604B1 (en) | 2002-05-10 | 2007-07-31 | Vasmo, Inc. | Medical devices for occlusion of blood flow |
AU2006203585B2 (en) * | 2002-05-31 | 2008-11-06 | Materials Modification, Inc. | A hemostatic composition |
US7670623B2 (en) * | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
AU2003279807A1 (en) | 2002-10-03 | 2004-04-23 | The Board Of Trustees Of The University Of Arkansas | Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same |
GB2393728A (en) * | 2002-10-04 | 2004-04-07 | Nanomagnetics Ltd | Magnetic nanoparticles |
AU2003274417A1 (en) * | 2002-10-30 | 2004-05-25 | Council Of Scientific And Industrial Research | Process for preparing nanosized acicular magnetic maghemite phase iron oxide particles |
US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040109824A1 (en) * | 2002-12-06 | 2004-06-10 | Hinds Kathleen Allison | Particles for imaging cells |
AU2003900335A0 (en) * | 2003-01-22 | 2003-02-13 | Sirtex Medical Limited | Microparticles for selectively targeted hyperthermia |
US7229600B2 (en) * | 2003-01-31 | 2007-06-12 | Nanoproducts Corporation | Nanoparticles of rare earth oxides |
DE10331439B3 (de) * | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
US7007972B1 (en) | 2003-03-10 | 2006-03-07 | Materials Modification, Inc. | Method and airbag inflation apparatus employing magnetic fluid |
US6982501B1 (en) | 2003-05-19 | 2006-01-03 | Materials Modification, Inc. | Magnetic fluid power generator device and method for generating power |
US7118727B2 (en) * | 2003-06-16 | 2006-10-10 | General Electric Company | Method of making oxide particles |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
GB0316912D0 (en) | 2003-07-18 | 2003-08-20 | Oxford Instr Superconductivity | Therapeutic treatment |
US7200956B1 (en) | 2003-07-23 | 2007-04-10 | Materials Modification, Inc. | Magnetic fluid cushioning device for a footwear or shoe |
TW593158B (en) * | 2003-07-31 | 2004-06-21 | Ind Tech Res Inst | Magnetic nanoparticle |
US7504082B2 (en) * | 2003-07-31 | 2009-03-17 | Industrial Technology Research Institute | Magnetic nanoparticles comprising Gadolinium and method of fabrication |
US7396589B2 (en) * | 2003-07-31 | 2008-07-08 | Industrial Technology Research Institute | Core-shell magnetic nanoparticles comprising an inner-transition element |
US7448389B1 (en) | 2003-10-10 | 2008-11-11 | Materials Modification, Inc. | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid |
CN100502948C (zh) * | 2003-10-22 | 2009-06-24 | 复旦大学附属中山医院 | 一种磁性高分子纳米微球载药系统及其制备方法 |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
US20070003482A1 (en) * | 2004-01-15 | 2007-01-04 | Koninklijke Philips Electronic, N.V. | Ultrasound contrast agents for molecular imaging |
WO2005070471A2 (en) * | 2004-01-20 | 2005-08-04 | Alnis Biosciences, Inc. | Articles comprising magnetic material and bioactive agents |
FR2867180B1 (fr) * | 2004-03-02 | 2006-06-16 | Univ Claude Bernard Lyon | Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation |
DE102004013637A1 (de) | 2004-03-19 | 2005-10-13 | Capsulution Nanoscience Ag | Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
EP1642648A1 (de) * | 2004-09-30 | 2006-04-05 | Roche Diagnostics GmbH | Vorrichtung und Verfahren zum Einstellen einer Temperatur einer Flüssigkeit |
RU2007127314A (ru) * | 2004-12-17 | 2009-01-27 | Конинклейке Филипс Электроникс Н.В. (Nl) | Контрастные средства или терапевтические средства направленной доставки для молекулярной визуализации и терапии |
US20070150051A1 (en) * | 2005-01-10 | 2007-06-28 | Duke Fiduciary, Llc | Vascular implants and methods of fabricating the same |
US8287583B2 (en) * | 2005-01-10 | 2012-10-16 | Taheri Laduca Llc | Apparatus and method for deploying an implantable device within the body |
US20100041983A9 (en) * | 2005-04-04 | 2010-02-18 | Elisha Rabinovitz | Device and method for pathology detection |
WO2006106507A2 (en) * | 2005-04-04 | 2006-10-12 | Given Imaging Ltd. | Device and method for pathology detection |
DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
CZ301067B6 (cs) * | 2006-02-24 | 2009-10-29 | Ústav makromolekulární chemie AV CR | Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití |
EP2023813A4 (en) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | MAGNETIC MICROPARTICLES COMPRISING ORGANIC SUBSTANCES |
BRPI0721148B8 (pt) | 2006-12-18 | 2021-05-25 | Colorobbia Italiana Spa | nanopartículas magnéticas para aplicação em hipertermia, preparação destas e uso de construtos apresentando aplicação farmacológica |
US8399022B2 (en) * | 2007-01-05 | 2013-03-19 | Tokyo Institute Of Technology | Spherical ferrite nanoparticles and method for producing the same |
EP2104468A2 (en) * | 2007-01-08 | 2009-09-30 | Gross, Yossi | In-situ filter |
US8597720B2 (en) | 2007-01-21 | 2013-12-03 | Hemoteq Ag | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
WO2008098252A2 (en) | 2007-02-09 | 2008-08-14 | Taheri Laduca Llc | Vascular implants and methods of fabricating the same |
US8512697B2 (en) * | 2007-05-16 | 2013-08-20 | The University Of North Carolina At Chapel Hill | Delivery of micro- and nanoparticles with blood platelets |
DE102007028777A1 (de) * | 2007-06-22 | 2008-12-24 | Carl Zeiss Meditec Ag | Transportvorrichtung |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
FR2922106B1 (fr) * | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
US9943490B2 (en) * | 2007-11-05 | 2018-04-17 | The Trustees Of Princeton University | Composite flash-precipitated nanoparticles |
US20100248260A1 (en) * | 2007-12-05 | 2010-09-30 | Massachusetts Institute Of Technology | Glycosaminoglycan-coated particles and uses thereof |
US8246932B2 (en) * | 2008-03-28 | 2012-08-21 | General Electric Company | Non-radioactive traceable metal isotope-enriched nanoparticles and method of their use for determining biodistribution |
ES2519476T3 (es) * | 2008-05-16 | 2014-11-07 | The University Of Sydney | Composiciones administrables |
US20110291049A1 (en) * | 2008-06-10 | 2011-12-01 | Board Of Trustees Of The University Of Arkansas | Indium arsenide nanocrystals and methods of making the same |
US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
WO2010120905A2 (en) * | 2009-04-15 | 2010-10-21 | Board Of Trustees Of Michigan State University | Novel nano-probes for molecular imaging and targeted therapy of diseases |
US10369256B2 (en) | 2009-07-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
WO2011008393A2 (en) * | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US20120269896A1 (en) | 2009-11-20 | 2012-10-25 | Toshiyuki Hakata | Magnetic iron oxide fine particles, and magnetic particle-containing water dispersion and process for producing the same |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
US10192660B2 (en) * | 2010-07-02 | 2019-01-29 | Sri Lanka Institute of Nanotechnology (Pvt) Ltd. | Process for preparation of nanoparticles from magnetite ore |
WO2012031236A1 (en) | 2010-09-02 | 2012-03-08 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US10398668B2 (en) | 2010-10-19 | 2019-09-03 | The Board Of Regents Of The University Of Oklahoma | Glutamate treatment of cardiovascular disorders |
US9744235B2 (en) | 2010-10-19 | 2017-08-29 | The Board Of Regents Of The University Of Oklahoma | Treatment of cardiovascular disorders with targeted nanoparticles |
US8740872B2 (en) | 2010-10-19 | 2014-06-03 | The Board Of Regents Of The University Of Oklahoma | Magnetically-targeted treatment for cardiac disorders |
WO2013022458A1 (en) | 2011-08-05 | 2013-02-14 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
EP2982652A1 (en) * | 2014-08-08 | 2016-02-10 | Universität für Bodenkultur Wien | Ultra-dense shell core-shell nanoparticles |
WO2016043680A1 (en) * | 2014-09-17 | 2016-03-24 | Erol Bülent | Development of magnetic-micro particles that provide controlled glycosaminoglycan (gag) release and the intravesical usage of it in interstitial cystitis |
KR102147451B1 (ko) * | 2017-07-21 | 2020-08-24 | 네오-나노메딕스.인크 | 생체 적합적 자기장에서 거대 자기 발열이 가능한 알칼리금속 또는 알칼리토금속이 도핑된 산화철 나노입자 및 그의 제조방법 |
JP7217473B2 (ja) * | 2017-11-06 | 2023-02-03 | コニカミノルタ株式会社 | ハイドロゲル粒子およびその製造方法、ハイドロゲル粒子を内包する細胞または細胞構造体、ハイドロゲル粒子を用いた細胞活性の評価方法、並びにハイドロゲル粒子の徐放性製剤としての使用 |
ES2898224T3 (es) | 2018-09-10 | 2022-03-04 | Ivoclar Vivadent Ag | Material dental con partículas magnéticas con apantallamiento de color mejorado |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913521B2 (ja) * | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
US4267234A (en) * | 1978-03-17 | 1981-05-12 | California Institute Of Technology | Polyglutaraldehyde synthesis and protein bonding substrates |
US4247406A (en) * | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4731239A (en) * | 1983-01-10 | 1988-03-15 | Gordon Robert T | Method for enhancing NMR imaging; and diagnostic use |
US4735796A (en) * | 1983-12-08 | 1988-04-05 | Gordon Robert T | Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease |
US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
PT81498B (pt) * | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
EP0247156B1 (en) * | 1985-11-18 | 1993-06-23 | Access Pharmaceuticals Inc. | Polychelating agents for image and spectral enhancement (and spectral shift) |
US5055288A (en) * | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
US5141739A (en) * | 1986-07-03 | 1992-08-25 | Advanced Magnetics, Inc. | Delivery of x-ray contrast agents using receptor mediated endocytosis |
DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
DE3812816A1 (de) * | 1988-04-16 | 1989-11-02 | Lawaczeck Ruediger Dipl Phys P | Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung |
US4965007A (en) * | 1988-05-10 | 1990-10-23 | Eastman Kodak Company | Encapsulated superparamagnetic particles |
ATE139431T1 (de) * | 1988-08-04 | 1996-07-15 | Advanced Magnetics Inc | Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri |
WO1990001939A1 (en) * | 1988-08-19 | 1990-03-08 | Meito Sangyo Kabushiki Kaisha | Agent for thermotherapy |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
AU628403B2 (en) * | 1988-09-29 | 1992-09-17 | Access Pharmaceuticals, Inc. | Methods and compositions for magnetic resonance imaging |
FR2652741B1 (fr) * | 1989-10-10 | 1994-03-04 | Laboratoires Care System | Composition antimicrobienne pour application sur la peau, applications comme deodorant corporel et bactericide cutane. |
EP0526503B1 (en) * | 1990-04-10 | 1997-06-04 | Imarx Pharmaceutical Corp. | Polymers as contrast media for magnetic resonance imaging |
FR2660864A1 (fr) * | 1990-04-13 | 1991-10-18 | Guerbet Sa | Composition de contraste, procede de preparation de cette composition et application a l'imagerie. |
US5143716A (en) * | 1991-02-01 | 1992-09-01 | Unger Evan C | Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region |
-
1991
- 1991-05-28 DE DE4117782A patent/DE4117782C2/de not_active Expired - Lifetime
-
1992
- 1992-04-13 ES ES92250084T patent/ES2106134T3/es not_active Expired - Lifetime
- 1992-04-13 DE DE59208743T patent/DE59208743D1/de not_active Expired - Fee Related
- 1992-04-13 DK DK92250084.8T patent/DK0516252T3/da active
- 1992-04-13 AT AT92250084T patent/ATE156021T1/de not_active IP Right Cessation
- 1992-04-13 EP EP92250084A patent/EP0516252B1/de not_active Expired - Lifetime
- 1992-05-05 NO NO921767A patent/NO305105B1/no unknown
- 1992-05-07 ZA ZA923299A patent/ZA923299B/xx unknown
- 1992-05-08 NZ NZ242669A patent/NZ242669A/en unknown
- 1992-05-11 AU AU16184/92A patent/AU653220B2/en not_active Ceased
- 1992-05-13 CA CA002068632A patent/CA2068632C/en not_active Expired - Fee Related
- 1992-05-13 US US07/882,130 patent/US5427767A/en not_active Expired - Lifetime
- 1992-05-20 IL IL10192992A patent/IL101929A/en not_active IP Right Cessation
- 1992-05-28 JP JP13728592A patent/JP3306810B2/ja not_active Expired - Fee Related
- 1992-07-01 IE IE159592A patent/IE921595A1/en not_active IP Right Cessation
-
1997
- 1997-10-01 GR GR970402545T patent/GR3024898T3/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0783325B2 (en) † | 1994-09-27 | 2004-03-31 | Amersham Health AS | Contrast agent |
Also Published As
Publication number | Publication date |
---|---|
IL101929A (en) | 1994-08-26 |
IE921595A1 (en) | 1992-12-02 |
NO921767D0 (no) | 1992-05-05 |
DE4117782C2 (de) | 1997-07-17 |
DE59208743D1 (de) | 1997-09-04 |
JP3306810B2 (ja) | 2002-07-24 |
DE4117782A1 (de) | 1992-12-03 |
DK0516252T3 (da) | 1997-08-25 |
US5427767A (en) | 1995-06-27 |
NO921767L (no) | 1992-11-30 |
EP0516252B1 (de) | 1997-07-30 |
EP0516252A3 (en) | 1993-07-28 |
NO305105B1 (no) | 1999-04-06 |
CA2068632A1 (en) | 1992-11-29 |
JPH07122410A (ja) | 1995-05-12 |
AU653220B2 (en) | 1994-09-22 |
CA2068632C (en) | 2002-10-01 |
GR3024898T3 (en) | 1998-01-30 |
AU1618492A (en) | 1992-12-03 |
IL101929A0 (en) | 1992-12-30 |
ATE156021T1 (de) | 1997-08-15 |
ES2106134T3 (es) | 1997-11-01 |
NZ242669A (en) | 1995-08-28 |
EP0516252A2 (de) | 1992-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA923299B (en) | Nanocrystalline magnetic iron oxide particles | |
DE3060602D1 (en) | Iron oxide pigments in the form of platelets, process for their preparation and their use | |
EP0455113A3 (en) | Fe based soft magnetic alloy, magnetic material containing same, and magnetic apparatus using the magnetic materials | |
HU9503809D0 (en) | Preparation for improving the blood supply containing hard magnetic particles | |
DE3063654D1 (en) | Modified acicular magnetic iron oxide, process for its production and its use in producing magnetic-recording supports | |
DE69020620D1 (de) | Verfahren zum Herstellen von kornorientierten Elektrostahlblechen mit hervorragenden magnetischen Eigenschaften. | |
DE68923544D1 (de) | Magnetische Eisenoxydteilchen und Verfahren zu ihrer Herstellung. | |
TR199801001A2 (xx) | Yumu�ak bir manyetik malzemeden yap�lm�� bir komponentin, bir manyetik alanda �s�l i�lemi i�in proses. | |
DE3061361D1 (en) | Process for producing ferromagnetic chromium dioxide, and its use in producing magnetic recording carriers | |
EP0421213A3 (en) | Chromium containing magnetic iron oxide pigments process for their fabrication and their application | |
EP0165536A3 (en) | Magnetic pigments mainly containing iron, process for their production and their use | |
DE3065058D1 (en) | Process for preparing ferromagnetic acicular iron particles, and their use | |
EP0024692A3 (en) | Process for preparing acicular ferromagnetic iron particles, and their use | |
EP0332990A3 (en) | Particulate magnetic hexaferrite pigments containing potassium from precipitated magnetite, process for their production and their use | |
EP0320863A3 (en) | Ferromagnetic metallic acicular particles, mainly iron ones, and process for their production | |
DE3889600D1 (de) | Kornorientierte Elektrobleche mit sehr geringen Eisenverlusten und Verfahren zum Herstellen dieser Bleche. | |
DE68925157D1 (de) | Plättchenförmige feine Ferritteilchen, geeignet zur Verwendung bei magnetischer Aufzeichnung und Verfahren zur Herstellung derselben | |
AU8174691A (en) | Reducing chelating agents, their technetium and rhenium complexes, process for their production as well as their use in diagnosis and treatment | |
JPS55115902A (en) | Production of needle like ferromagnetic iron particle | |
DE69106293D1 (de) | Nadelförmige ferromagnetische Eisenoxydteilchen und Verfahren zu ihrer Herstellung. | |
GR3004570T3 (xx) | ||
IL50893A (en) | Microbiological process for the production of 3a -h-4 -(3'-propanol)-7a -methylhexahydro-1,5-indandione-hemiketal and a new mutant used in this process | |
EP0376033A3 (en) | Process for preparing magnetic iron oxides, and pigments thus obtained | |
DE69406499D1 (de) | Kobalt enthaltende Eisenoxidpigmente, Erzeugungsverfahren und diese enthaltendes magnetisches Aufzeichnungsmedium | |
KE3193A (en) | Asymmetric 1:2 cobalt complexes,their production and use |